AAPL   323.89 (+0.17%)
MSFT   184.21 (-0.38%)
FB   230.26 (-1.06%)
GOOGL   1,437.37 (-0.34%)
AMZN   2,470.33 (-0.08%)
NVDA   350.88 (-0.60%)
CGC   16.83 (+4.28%)
BABA   217.92 (+1.67%)
GE   7.27 (+3.12%)
TSLA   890.70 (+1.04%)
AMD   52.68 (-1.62%)
T   31.42 (+1.39%)
ACB   14.46 (-0.48%)
GILD   73.93 (+0.91%)
DIS   121.44 (+2.27%)
NFLX   421.11 (-1.45%)
BAC   26.05 (+4.87%)
BA   166.08 (+8.33%)
AAPL   323.89 (+0.17%)
MSFT   184.21 (-0.38%)
FB   230.26 (-1.06%)
GOOGL   1,437.37 (-0.34%)
AMZN   2,470.33 (-0.08%)
NVDA   350.88 (-0.60%)
CGC   16.83 (+4.28%)
BABA   217.92 (+1.67%)
GE   7.27 (+3.12%)
TSLA   890.70 (+1.04%)
AMD   52.68 (-1.62%)
T   31.42 (+1.39%)
ACB   14.46 (-0.48%)
GILD   73.93 (+0.91%)
DIS   121.44 (+2.27%)
NFLX   421.11 (-1.45%)
BAC   26.05 (+4.87%)
BA   166.08 (+8.33%)
AAPL   323.89 (+0.17%)
MSFT   184.21 (-0.38%)
FB   230.26 (-1.06%)
GOOGL   1,437.37 (-0.34%)
AMZN   2,470.33 (-0.08%)
NVDA   350.88 (-0.60%)
CGC   16.83 (+4.28%)
BABA   217.92 (+1.67%)
GE   7.27 (+3.12%)
TSLA   890.70 (+1.04%)
AMD   52.68 (-1.62%)
T   31.42 (+1.39%)
ACB   14.46 (-0.48%)
GILD   73.93 (+0.91%)
DIS   121.44 (+2.27%)
NFLX   421.11 (-1.45%)
BAC   26.05 (+4.87%)
BA   166.08 (+8.33%)
AAPL   323.89 (+0.17%)
MSFT   184.21 (-0.38%)
FB   230.26 (-1.06%)
GOOGL   1,437.37 (-0.34%)
AMZN   2,470.33 (-0.08%)
NVDA   350.88 (-0.60%)
CGC   16.83 (+4.28%)
BABA   217.92 (+1.67%)
GE   7.27 (+3.12%)
TSLA   890.70 (+1.04%)
AMD   52.68 (-1.62%)
T   31.42 (+1.39%)
ACB   14.46 (-0.48%)
GILD   73.93 (+0.91%)
DIS   121.44 (+2.27%)
NFLX   421.11 (-1.45%)
BAC   26.05 (+4.87%)
BA   166.08 (+8.33%)
Log in

NYSE:ABBVAbbVie Stock Price, Forecast & News

$90.13
-0.91 (-1.00 %)
(As of 06/3/2020 11:55 AM ET)
Add
Compare
Today's Range
$89.60
Now: $90.13
$91.50
50-Day Range
$79.75
MA: $86.48
$93.02
52-Week Range
$62.55
Now: $90.13
$97.86
Volume3.10 million shs
Average Volume13.10 million shs
Market Capitalization$133.10 billion
P/E Ratio15.95
Dividend Yield5.20%
Beta0.85
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More
AbbVie logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 5.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.83 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.27 billion
Cash Flow$10.27 per share
Book Value($5.53) per share

Profitability

Net Income$7.88 billion

Miscellaneous

Employees30,000
Outstanding Shares1,476,740,000
Market Cap$133.10 billion
Next Earnings Date7/24/2020 (Estimated)
OptionableOptionable

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

AbbVie (NYSE:ABBV) Frequently Asked Questions

How has AbbVie's stock been impacted by COVID-19 (Coronavirus)?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ABBV shares have increased by 6.1% and is now trading at $90.06. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AbbVie?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AbbVie.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 24th 2020. View our earnings forecast for AbbVie.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) announced its earnings results on Friday, May, 1st. The company reported $2.42 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.25 by $0.17. The firm earned $8.62 billion during the quarter, compared to analysts' expectations of $8.31 billion. AbbVie had a negative return on equity of 169.80% and a net margin of 24.77%. AbbVie's revenue was up 10.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.14 EPS. View AbbVie's earnings history.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Thursday, February 20th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.18 per share on Friday, May 15th. This represents a $4.72 dividend on an annualized basis and a yield of 5.24%. The ex-dividend date is Tuesday, April 14th. View AbbVie's dividend history.

How will AbbVie's stock buyback program work?

AbbVie announced that its board has initiated a stock repurchase plan on Thursday, December 13th 2018, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 3.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's board believes its shares are undervalued.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY 2020 After-Hours earnings guidance on Friday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $50-50 billion.

What price target have analysts set for ABBV?

14 Wall Street analysts have issued twelve-month price targets for AbbVie's stock. Their forecasts range from $90.00 to $122.00. On average, they expect AbbVie's share price to reach $101.31 in the next year. This suggests a possible upside of 12.5% from the stock's current price. View analysts' price targets for AbbVie.

Has AbbVie been receiving favorable news coverage?

Headlines about ABBV stock have been trending neutral recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AbbVie earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutAbbVie.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.87%), State Street Corp (4.62%), Capital Research Global Investors (3.33%), Geode Capital Management LLC (1.75%), Bank of New York Mellon Corp (1.26%) and Janus Henderson Group PLC (0.78%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Two Sigma Advisers LP, Capital International Investors, Los Angeles Capital Management & Equity Research Inc., Invesco Ltd., American International Group Inc., Vaughan Nelson Investment Management L.P., and MERIAN GLOBAL INVESTORS UK Ltd. Company insiders that have sold AbbVie company stock in the last year include Jeffrey Ryan Stewart, and Timothy J Richmond. View insider buying and selling activity for AbbVie.

Which institutional investors are buying AbbVie stock?

ABBV stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Bank of New York Mellon Corp, BlackRock Inc., Advisor Group Holdings Inc., Geode Capital Management LLC, AQR Capital Management LLC, Bahl & Gaynor Inc., and Camber Capital Management LP. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $90.06.

How big of a company is AbbVie?

AbbVie has a market capitalization of $133.00 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.